Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis

Brahmbhatt, T.; Hari, P.; Cinquegrani, M.; Kumar, N.; Komorowski, R.; Migrino, R. Q.
November 2008
British Journal of Radiology;Nov2008, Vol. 81 Issue 971, pe272
Academic Journal
We report the first observation of diffuse subendocardial and myocardial delayed enhancement on cardiac MRI in a 50-year-old patient with recurrent multiple myeloma but without evidence of amyloidosis. She presented with advanced heart failure and severe restrictive cardiomyopathy. Myocardial biopsy revealed endomyocardial fibrosis. The case was associated with development of multiple arterial and venous thromboses and a fatal course. Because of the fatal outcome, the prognostic significance of delayed enhancement on MRI in multiple myeloma patients may need to be further investigated.


Related Articles

  • The many faces of sarcoidosis: asymptomatic muscle mass mimicking giant-cell tumor. Kolilekas, Likurgos; Triantafillidou, Christina; Manali, Effrosyni; Rontogianni, Dimitra; Chatziioannou, Sophia; Papiris, Spyros // Rheumatology International;Sep2009, Vol. 29 Issue 11, p1389 

    Sarcoidosis is a chronic, multisystem granulomatous disease of unknown etiology. Muscle involvement is frequent, but often asymptomatic. There are three forms of muscular sarcoidosis: only the nodular type can be recognized by imaging. MRI and 18F-FDG PET–CT are the best methods to...

  • Amyloid in the cardiovascular system: a review. Kholová, I.; Nessen, H. W. M. // Journal of Clinical Pathology;Feb2005, Vol. 58 Issue 2, p125 

    The cardiovascular system is a common target of amyloidosis. This review presents the current clinical and diagnostic approach to amyloidosis, with the emphasis on cardiovascular involvement. It summarises recent nomenclature, classification, and pathogenesis of amyloidosis. In addition,...

  • From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. Dziadzio, Magdalena; Anastassiades, Constantinos; Hawkins, Philip; Potter, Michael; Gabrielli, Armando; Brough, Geraldine; Black, Carol; Denton, Christopher // Clinical Rheumatology;Feb2006, Vol. 25 Issue 1, p3 

    Scleredema (also called scleredema of Buschke) is a fibromucinous connective tissue disorder of unknown cause that belongs to a group of scleroderma-like disorders. We report the case of a 64-year-old lady with long-standing scleredema, associated with a paraprotein, and progressing to multiple...

  • Skin Involvement in Generalized Amyloidosis. Rubinow, Alan; Cohen, Alan S. // Annals of Internal Medicine;Jun78, Vol. 88 Issue 6, p781 

    Provides information on a study which examined clinically involved and uninvolved skin in 50 patients with primary and secondary amyloidosis. Description of primary and multiple myeloma-associated amyloidosis; Extent of amyloid involvement in skin biopsies in primary and multiple...

  • Immunoglobulin light chains, glycosaminoglycans, and amyloid. Stevens, F. J.; Kisilevsky, R. // Cellular & Molecular Life Sciences;Mar2000, Vol. 57 Issue 3, p441 

    Immunoglobulin light chains are the precursor proteins for fibrils that are formed during primary amyloidosis and in amyloidosis associated with multiple myeloma. As found for the approximately 20 currently described forms of focal, localized, or systemic amyloidoses, light chain-related fibrils...

  • Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Dispenzieri, A; Seenithamby, K; Lacy, M Q; Kumar, S K; Buadi, F K; Hayman, S R; Dingli, D; Litzow, M R; Gastineau, D A; Inwards, D J; Micallef, I N; Ansell, S M; Johnston, P B; Porrata, L F; Patnaik, M M; Hogan, W J; Gertz, M A A // Bone Marrow Transplantation;Oct2013, Vol. 48 Issue 10, p1302 

    The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby...

  • Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. Almeida, M. R.; Gales, L.; Damas, A. M.; Cardoso, I.; Saraiva, M. J. // Current Drug Targets - CNS & Neurological Disorders;Oct2005, Vol. 4 Issue 5, p587 

    In transthyretin (TTR) amyloidosis TTR variants deposit as amyloid fibrils giving origin, in most cases, to peripheral polyneuropathy, cardiomyopathy, carpal tunnel syndrome and/or amyloid deposition in the eye. More than eighty TTR variants are known, most of them being pathogenic. The...

  • Typing of Amyloidosis in Renal Biopsies: Diagnostic Pitfalls. Satoskar, Anjali A.; Burdge, Kelly; Cowden, Daniel J.; Nadasdy, Gyongyi M.; Hebert, Lee A.; Nadasdy, Tibor // Archives of Pathology & Laboratory Medicine;Jun2007, Vol. 131 Issue 6, p917 

    Context.—Amyloidosis represents a group of diseases with extracellular deposition of congophilic fibrils of similar morphology but differing chemical composition. The types commonly involving the kidney are AL (light chain amyloid) and AA (serum amyloid A). Familial amyloidosis can also...

  • Pilot Study of the Reducing Effect on Amyloidosis In Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5'Untranslated Region. Tucker, Stephanie; Ahl, Michelle; Bush, Ashley; Westaway, David; Xudong Huang; Rogers, Jack T. // Current Alzheimer Research;Apr2005, Vol. 2 Issue 2, p249 

    A pilot study was conducted employing a well known mouse model for Alzheimer's disease to evaluate the anti-amyloid efficacy of three FDA pre-approved drugs. Paroxetine (SSRI and APP 5'UTR directed lead compound), Nacetyl cysteine (antioxidant), and erythromycin (macrolide antibiotic) were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics